# S.R.I.W.

> S.R.I.W. is a VC fund in Liège backing Health Care and Biotechnology. See 111 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Liège, Belgium
- Total investments: 111
- Last investment: Jun 2023
- Lead investor: 21%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/1826108
- Website: http://www.sriw.be

S.R.I.W. is a VC fund in Liège focused on Health Care and Biotechnology. The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.

## Contacts

5 contacts available for S.R.I.W.. Shizune tracks 5 team members at S.R.I.W.. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/s-r-i-w?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $411k–$31M |
| Series B | $1.6M–$75M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 22 | 20% |
| Biotechnology | 21 | 19% |
| Manufacturing | 13 | 12% |
| Software | 12 | 11% |
| Pharmaceutical | 10 | 9% |

111 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 51 | 46% |
| Series A | 17 | 15% |
| Series B | 15 | 14% |
| Seed | 7 | 6% |
| Series C | 4 | 4% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 83 | 75% |
| United States | 3 | 3% |
| Spain | 1 | 1% |
| France | 1 | 1% |
| Luxembourg | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Damien Lourtie | Chief Financial Officer | 1 | https://shizune.co/investors/profile/damien-lourtie |
| Gery Lefebvre | Investment Manager | 2 | https://shizune.co/investors/profile/gery-lefebvre |
| Jean-Pascal LABILLE | Chairman | 0 | https://shizune.co/investors/profile/jean-pascal-labille |
| Philippe Degive | Investment Manager | 3 | https://shizune.co/investors/profile/philippe-degive |
| Thibaut Claes | Investment Manager | 0 | https://shizune.co/investors/profile/thibaut-claes |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Santero Therapeutics | Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms. | $8.6M | Series A | Jun 07, 2023 |  |
| Intressa Vascular | Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection. | $12M |  | Oct 25, 2022 |  |
| Intressa Vascular | Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection. | $6M | Grant | Oct 25, 2022 |  |
| Univercells | Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. | $43.3M | Series D | Oct 17, 2022 |  |
| BOTALYS | OUR MISSIONWe are Botanical Explorers seeking the next frontier of plant health benefits while preserving wild biotopes. We firmly believe that medicinal plants deserve a new standard of uncompromising quality, and we are committed to explore their health potential further while respecting the planet. Hence, our two core values: Explore &Respect.OUR VISIONIndoor Precision Farming offers a unique opportunity to sustainably grow potent medicinal plants. We have developed our own indoor farming approach under ultra-clean conditions. Our cultivation facilities are one of the largest vertical farms in Europe. There, by optimizing the growth environment, we ensure that our botanicals reach their full potential in terms of Health benefits, bringing full-spectrum product to the next level, and combining Wild Quality with Lab purity.OUR PRODUCTWith more than 3000 years of medicinal tradition and more than 5000 scientific publications about its health benefits, Korean red ginseng (Panax ginseng CA Meyer) is, without a doubt, the most precious and revered medicinal plant in the world. At BOTALYS, we are shaping its molecular profile, making our full-spectrum ginseng root powder comparable to a 20 years old wild Korean ginseng specimen.And ginseng is just the first botanical milestone of our journey… | $6.6M | Series B | Oct 04, 2022 |  |
| BOTALYS | OUR MISSIONWe are Botanical Explorers seeking the next frontier of plant health benefits while preserving wild biotopes. We firmly believe that medicinal plants deserve a new standard of uncompromising quality, and we are committed to explore their health potential further while respecting the planet. Hence, our two core values: Explore &Respect.OUR VISIONIndoor Precision Farming offers a unique opportunity to sustainably grow potent medicinal plants. We have developed our own indoor farming approach under ultra-clean conditions. Our cultivation facilities are one of the largest vertical farms in Europe. There, by optimizing the growth environment, we ensure that our botanicals reach their full potential in terms of Health benefits, bringing full-spectrum product to the next level, and combining Wild Quality with Lab purity.OUR PRODUCTWith more than 3000 years of medicinal tradition and more than 5000 scientific publications about its health benefits, Korean red ginseng (Panax ginseng CA Meyer) is, without a doubt, the most precious and revered medicinal plant in the world. At BOTALYS, we are shaping its molecular profile, making our full-spectrum ginseng root powder comparable to a 20 years old wild Korean ginseng specimen.And ginseng is just the first botanical milestone of our journey… | $271K | Secondary Market | Oct 04, 2022 |  |
| BOTALYS | OUR MISSIONWe are Botanical Explorers seeking the next frontier of plant health benefits while preserving wild biotopes. We firmly believe that medicinal plants deserve a new standard of uncompromising quality, and we are committed to explore their health potential further while respecting the planet. Hence, our two core values: Explore &Respect.OUR VISIONIndoor Precision Farming offers a unique opportunity to sustainably grow potent medicinal plants. We have developed our own indoor farming approach under ultra-clean conditions. Our cultivation facilities are one of the largest vertical farms in Europe. There, by optimizing the growth environment, we ensure that our botanicals reach their full potential in terms of Health benefits, bringing full-spectrum product to the next level, and combining Wild Quality with Lab purity.OUR PRODUCTWith more than 3000 years of medicinal tradition and more than 5000 scientific publications about its health benefits, Korean red ginseng (Panax ginseng CA Meyer) is, without a doubt, the most precious and revered medicinal plant in the world. At BOTALYS, we are shaping its molecular profile, making our full-spectrum ginseng root powder comparable to a 20 years old wild Korean ginseng specimen.And ginseng is just the first botanical milestone of our journey… | $987K | Convertible Note | Oct 04, 2022 |  |
| I-care Group | I-care offers products, training, and services to its industrial customers. | $54.9M |  | Sep 30, 2022 |  |
| I-care Group | I-care offers products, training, and services to its industrial customers. | $49M | Series C | Sep 30, 2022 |  |
| Aerospacelab | Aerospacelab is a company established near Brussels aiming at tackling some of the most challenging problems with a completely different paradigm. | $45.5M | Series B | Feb 16, 2022 |  |

10 of 111 investments shown.

## Co-investors
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 19 deals together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 14 deals together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 10 deals together
- [Vives Louvain Technology Fund](https://shizune.co/investors/profile/vives-fund) — VC Fund, 10 deals together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 7 deals together
- [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)
- [Biotech VC Funds in Belgium](https://shizune.co/investors/biotech-vc-funds-belgium)

## FAQ

### What does S.R.I.W. invest in?

S.R.I.W. invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Funding Round and Series A stage. Most of the 111 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is S.R.I.W.'s check size?

S.R.I.W. typically joins rounds of $411k–$31M at Series A and $1.6M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds S.R.I.W. participates in.

### How do I contact S.R.I.W.?

Public channels for S.R.I.W. include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at S.R.I.W.?

The team at S.R.I.W. includes Damien Lourtie (Chief Financial Officer), Gery Lefebvre (Investment Manager) and Jean-Pascal LABILLE (Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co